Home › Trials › NCT07151183
Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Understanding diagnosis, prognosis, and causes of panvascular disease

Official title: A Prospective Research on Diagnosis, Prognosis, and Mechanisms of Panvascular Disease

Run by Harbin Medical University · NCT07151183 · Data updated 2026-11-12

This project will collect medical records, DNA samples, and follow-up from adults with panvascular disease to see if linking clinical and genetic data can reveal causes and suggest better treatments.

More Cardiovascular Diseases trials

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment1000 (estimated)
SponsorHarbin Medical University
Academic / other
Locations1 site (Harbin, Heilongjiang)
StatusRecruiting
StartedDecember 1, 2024
Main results expectedDecember 31, 2030
Study endsDecember 31, 2030
Registry record updatedSeptember 3, 2025
Trial IDNCT07151183 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 to 80 with diagnosed or suspected panvascular disease (atherosclerotic lesions in two or more vascular regions) who can give informed consent are the intended participants.

Probably not a fit

Patients with severe hemodynamic instability, very low ejection fraction (<30%), severe arrhythmias or valvular disease, non-atherosclerotic coronary disorders, severe non-cardiovascular illness, pregnant or breastfeeding individuals, or those who decline consent are not likely to benefit from or be eligible for this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will create a standardized cohort of adults with panvascular disease by collecting detailed clinical records, biological samples (including DNA), and long-term follow-up data at Harbin Medical University. No interventions will be given; the study is observational and focuses on comprehensive data and sample collection. Investigators will apply statistical and multi-omics analyses to identify risk factors, molecular pathways, and prognostic markers across multiple vascular beds. The resulting database is intended as a resource for future mechanistic studies and to inform more precise prevention and treatment strategies.

Why it matters

Potential benefit: If successful, this resource could help identify molecular drivers and risk patterns that enable earlier detection and more personalized treatments for panvascular disease.

How similar studies have gone: Cohort and multi-omics research in cardiovascular disease have previously identified useful associations and biomarkers, but a standardized panvascular-focused cohort of this type is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Male or female aged 18 to 80 years old;
2. Diagnosed or suspected panvascular disease, defined as the presence of atherosclerotic lesions in at least two or more vascular regions, such as intracranial arteries, carotid arteries, coronary arteries, aorta, and peripheral arteries;
3. Voluntary participation in this study and provision of signed informed consent.

Exclusion Criteria:

1. Severe hemodynamic instability;
2. Severe cardiac dysfunction (EF \< 30%);
3. Severe arrhythmias;
4. Severe valvular heart disease;
5. Cardiomyopathy caused by non-coronary artery diseases;
6. Non-atherosclerotic coronary artery disease (e.g., coronary artery dissection, embolism, etc.);
7. Severe non-cardiovascular diseases;
8. Women who are pregnant or breastfeeding;
9. Individuals who refuse to provide signed informed consent.

Where it's running

  • Harbin Medical University
    Harbin, Heilongjiang, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Cardiovascular Diseases 365Harbin Medical University 11
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.